Benzinga—
Abbott's Strong AFib, Cardiac Device Data Fuels Heart-Rhythm Device Buzz
Shares of Abbott Laboratories Inc. (NYSE: ABT ) moved higher in Monday's premarket session after the company unveiled new clinical data supporting the effectiveness of its technologies designed to treat abnormal heart rhythms, particularly atrial fibrillation (AFib). The positive movement released on Saturday follows the release of new data from several clinical trials, highlighting the effectiveness of Abbott’s devices. data-variant="card" data-news-mode="manual" > Read Also: Also Read: Abbott Labs Annual Guidance Cut Overshadows Earnings Beat, Stock Cracks FlexPulse Study Shows High Success And Safety Rates New six-month findings from the FlexPulse IDE study provided early evidence supporting Abbott's TactiFlex Duo Ablation Catheter, Sensor Enabled, in treating complex AFib cases. The data also reinforced results previously observed in the ... Full story available on Benzinga.com